Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876915 · ClinicalTrials.gov registry record · Phase 3
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
A Phase 3 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 3
- Development phase
- 218
- Enrollment target
NCT00876915 is a Phase 3 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 218 participants.
The verdict
NCT00876915, a Phase 3 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 218 participants
- Enrollment target
Study Summary
Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening. The purpose of this study is to determine if a daily injection of a blood-thinner, dalteparin, for 12 weeks can safely and effectively reduce the frequency of blood clots. Dalteparin is currently approved for prevention of blood clots following surgery and in hospitalized patients but not specifically for cancer outpatients.
Interventions
- DRUG dalteparin injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00876915
The ClinicalTrials.gov registry entry for NCT00876915 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dalteparin injection is the first listed.
NCT00876915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00876915 about?
NCT00876915 is a clinical study titled "A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients". Some cancer patients starting a new chemotherapy regimen are likely to develop blood clots, also known as venous thromboembolism (VTE). Blood clots can cause symptoms and can occasionally be life-threatening. The purpose of this study is to determine if a daily injection of a blood-thinner, daltepar...
What is the current status of trial NCT00876915?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2009-07. Estimated completion is 2014-12.
What interventions are being tested in trial NCT00876915?
The interventions under investigation include: dalteparin injection (DRUG).
Who is sponsoring clinical trial NCT00876915?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.